Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · AdaptHealth (AHCO)

AdaptHealth Q3 revenue rises 10.9%; $184.8 million goodwill charge drives loss

Mixed Impact 4 of 5 earnings

AdaptHealth reported third-quarter 2026 net revenue of $745.6 million, up 10.9% from a year earlier, but a $184.8 million pre-tax goodwill write-down produced a net loss. The company raised its full-year 2026 revenue and Adjusted EBITDA guidance but lowered its free cash flow guidance, and it cleared the Hart-Scott-Rodino waiting period for the pending $235.0 million sale of its Diabetes Health business.

Key points

  • Q3 net revenue $745.6 million vs. $672.4 million; organic revenue growth of 12.8%
  • Q3 Adjusted EBITDA $141.9 million vs. $146.1 million, down 2.9%
  • 2026 guidance: revenue raised to $2.88-$2.90 billion; Adjusted EBITDA raised to $510-$525 million; free cash flow cut to $50-$75 million from $80-$120 million
  • Diabetes Health sale for $235.0 million in cash expected to close in early 2027

The filing

CompanyAdaptHealth (AHCO)
Form8-K, current report
Filed with the SECNov 3, 2026, 8:10 AM ET
Accession number0001628280-26-069116

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 7, 2026, 11:17 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.